Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prelude Therapeutics Inc PRLD

Healthcare Biotechnology
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789... see more

Recent & Breaking News (NDAQ:PRLD)

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2024

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

GlobeNewswire October 24, 2024

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

GlobeNewswire October 9, 2024

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

GlobeNewswire September 13, 2024

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

GlobeNewswire September 9, 2024

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2024

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

GlobeNewswire July 9, 2024

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

GlobeNewswire June 3, 2024

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

GlobeNewswire May 9, 2024

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 7, 2024

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

GlobeNewswire April 9, 2024

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

GlobeNewswire March 5, 2024

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

GlobeNewswire February 29, 2024

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

GlobeNewswire February 15, 2024

Prelude Therapeutics Announces $25 Million Private Placement

GlobeNewswire December 11, 2023

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

GlobeNewswire November 1, 2023

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

GlobeNewswire November 1, 2023

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

GlobeNewswire October 14, 2023

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

GlobeNewswire August 29, 2023

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 3, 2023